BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sapropterin Dihydrochloride (Kuvan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sapropterin Dihydrochloride (Kuvan)\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02947750-10342@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sapropterin Dihydrochloride (Kuvan): Phase 2 readout est. (NCT02947
 750)
DESCRIPTION:Sapropterin Dihydrochloride (Kuvan)\, phase 2.\nStudy: Neurovas
 cular Transduction During Exercise in Chronic Kidney Disease\nEstimated pr
 imary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sapropterin-dihydrochloride-kuvan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02947750
URL:https://assetmemo.bio/drug/sapropterin-dihydrochloride-kuvan#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07574034-10342@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sapropterin Dihydrochloride (Kuvan): Phase na readout est. (NCT0757
 4034)
DESCRIPTION:Sapropterin Dihydrochloride (Kuvan)\, phase na.\nStudy: A Singl
 e Patient Study of Sapropterin for Multisystem Smooth Muscle Dysfunction S
 yndrome\nEstimated primary completion: 1 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/sapropterin-dihydrochloride-kuvan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07574034
URL:https://assetmemo.bio/drug/sapropterin-dihydrochloride-kuvan#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312748-10342@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Sapropterin Dihydrochloride (Kuvan): Phase 1 readout est. (NCT06312
 748)
DESCRIPTION:Sapropterin Dihydrochloride (Kuvan)\, phase 1.\nStudy: Novel Ap
 proaches for Improving Vascular Function in Veterans With HFpEF\nEstimated
  primary completion: 30 September 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sapropterin-dihydrochloride-kuvan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06312748
URL:https://assetmemo.bio/drug/sapropterin-dihydrochloride-kuvan#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02966665-10342@assetmemo.bio
DTSTAMP:20261121T005033Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Sapropterin Dihydrochloride (Kuvan): Phase 1 readout est. (NCT02966
 665)
DESCRIPTION:Sapropterin Dihydrochloride (Kuvan)\, phase 1.\nStudy: : Vascul
 ar Function in Health and Disease\nEstimated primary completion: August 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sapropterin-dihyd
 rochloride-kuvan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT02966665
URL:https://assetmemo.bio/drug/sapropterin-dihydrochloride-kuvan#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
